Jul 8, 2026 07:01AM
Jul 8, 2026 07:01AM
May 12, 2026 07:30AM
Mar 19, 2026 04:07PM
Mar 19, 2026 08:30AM
Jan 13, 2026 07:06AM
Jan 12, 2026 08:00AM Mereo BioPharma extends cash runway to mid-2027 after setrusumab trial delays
Jan 12, 2026 08:00AM
Dec 29, 2025 01:24PM
Dec 29, 2025 08:32AM
Dec 29, 2025 08:31AM
Dec 18, 2025 03:49AM
Nov 10, 2025 04:01PM
Aug 19, 2025 08:32AM ashibio licenses vantictumab from Mereo for rare bone disorder treatment
Aug 19, 2025 08:30AM
Aug 12, 2025 07:35AM
Jul 9, 2025 04:05PM
Jul 9, 2025 04:05PM
Jul 1, 2025 01:00AM
May 13, 2025 07:30AM
Mar 26, 2025 07:30AM Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
Mar 5, 2025 07:30AM
Jan 12, 2025 11:05AM
Jan 7, 2025 07:30AM
Nov 14, 2024 07:30AM
Nov 12, 2024 07:30AM
Sep 12, 2024 05:35PM
Aug 13, 2024 08:00AM Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jun 14, 2024 07:51AM
Jun 14, 2024 07:50AM
Jun 12, 2024 08:12AM
Jun 11, 2024 05:47PM
May 30, 2024 07:30AM
May 15, 2024 04:01PM
Apr 3, 2024 07:30AM Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Mar 28, 2024 07:10AM
Mar 27, 2024 04:01PM
Mar 5, 2024 07:30AM
Jan 8, 2024 07:00AM
Oct 23, 2023 04:02PM
Oct 23, 2023 04:01PM
Oct 16, 2023 07:09AM Ultragenyx Pharma (RARE) and Mereo BioPharma (MREO) Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with OI
Oct 14, 2023 04:30PM
Oct 13, 2023 06:33AM
Sep 21, 2023 07:00AM
Sep 7, 2023 07:30AM
Aug 14, 2023 04:00PM
Jun 5, 2023 04:01PM
Jun 5, 2023 04:00PM Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
Jun 5, 2023 08:00AM

325,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All